Drug Profile


Alternative Names: AGS-16C3F; AGS-16M8F

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agensys
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma

Most Recent Events

  • 26 Apr 2017 Agensys and Astellas Pharma completes a phase I trial for Renal cell carcinoma (Metastatic disease, Second-line therapy or greater) in USA (NCT01672775)
  • 31 Jan 2017 Phase-II clinical trials in Renal cell carcinoma in Europe (IV) (Astellas Pharma pipeline, January 2017)
  • 01 Feb 2016 Phase-II clinical trials in Renal cell carcinoma (Second-line therapy or greater, Metastatic disease) in USA, Canada (IV) (NCT02639182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top